Anavex Life Sciences Corp. (LON: 0HFR)
London
· Delayed Price · Currency is GBP · Price in USD 9.12
-0.20 (-2.16%)
At close: Jan 31, 2025
Anavex Life Sciences Employees
Anavex Life Sciences had 42 employees as of September 30, 2024. The number of employees increased by 2 or 5.00% compared to the previous year.
Employees
42
Change (1Y)
2
Growth (1Y)
5.00%
Revenue / Employee
n/a
Profits / Employee
-763.90K GBP
Market Cap
632.54M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| AstraZeneca | 89,900 |
| GSK plc | 70,212 |
| Haleon | 25,408 |
| Smith & Nephew | 18,452 |
| Hikma Pharmaceuticals | 9,100 |
| ConvaTec Group | 10,136 |
| HUTCHMED (China) | 1,988 |
| Oxford Nanopore Technologies | 1,238 |
Anavex Life Sciences News
- 6 days ago - Anavex Life Sciences Announces Issuance of Blarcamesine (ANAVEX®2-73) Composition of Matter U.S. Patent Expanding its Intellectual Property Portfolio - GlobeNewsWire
- 18 days ago - Anavex Life Sciences Announces Peer-Reviewed Publication of Oral Blarcamesine Phase IIb/III Data in The Journal of Prevention of Alzheimer's Disease - GlobeNewsWire
- 20 days ago - New Phase IIb/III Clinical Data Demonstrates Over Three Years of Continuous Treatment with Oral Blarcamesine to Significantly Benefit Early Alzheimer's Disease Patients - Benzinga
- 20 days ago - New Phase IIb/III Clinical Data Demonstrates Over Three Years of Continuous Treatment with Oral Blarcamesine to Significantly Benefit Early Alzheimer's Disease Patients - GlobeNewsWire
- 21 days ago - Playing The Odds Of Anavex Alzheimer's Drug Approval - Seeking Alpha
- 23 days ago - The Misconceptions About Anavex Life Sciences' Blarcamesine Phase 2b/3 Trial In Alzheimer's Disease - Seeking Alpha
- 27 days ago - Anavex Life Sciences to Present at the 43rd Annual J.P. Morgan Healthcare Conference - GlobeNewsWire
- 5 weeks ago - Anavex Life Sciences: Jumping In On Time Ahead Of An Early Alzheimer's Decision - Seeking Alpha